Do analysts recommend LNAI or MDXH?

MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 186.56%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is LNAI or MDXH more profitable?

Lunai Bioworks has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% MDxHealth -33.46% N/A -24.25%

Do analysts prefer LNAI or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 1,310.26%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate LNAI or GOSS?

Gossamer Bio has a consensus target price of $3.20, indicating a potential upside of 1,740.14%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22

Is LNAI or GOSS more profitable?

Lunai Bioworks has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Gossamer Bio -235.00% N/A -112.04%

Which has higher valuation & earnings, QNCX or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is QNCX or LNAI more profitable?

Quince Therapeutics' return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts prefer LNAI or BYSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LNAI or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% BeyondSpring N/A N/A -28.88%

Lunai Bioworks (LNAI) Competitors

$2.40 +0.20 (+9.09%)

As of 04:00 PM Eastern

Compare

LNAI vs. MDXH, BTAI, GOSS, QNCX, and BYSI

Should you buy Lunai Bioworks stock or one of its competitors? Lunai Bioworks's main competitors and comparable companies include MDxHealth (MDXH), BioXcel Therapeutics (BTAI), Gossamer Bio (GOSS), Quince Therapeutics (QNCX), and BeyondSpring (BYSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lunai Bioworks compare to MDxHealth?

Lunai Bioworks (NASDAQ:LNAI) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

In the previous week, MDxHealth had 4 more articles in the media than Lunai Bioworks. MarketBeat recorded 5 mentions for MDxHealth and 1 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.87 beat MDxHealth's score of 0.01 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Very Positive
MDxHealth	Neutral

Lunai Bioworks has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 186.56%. Given MDxHealth's stronger consensus rating and higher probable upside, analysts plainly believe MDxHealth is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Lunai Bioworks has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
MDxHealth	-33.46%	N/A	-24.25%

MDxHealth has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
MDxHealth	$107.88M	0.35	-$33.52M	-$0.72	N/A

71.4% of Lunai Bioworks shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Comparatively, 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

MDxHealth beats Lunai Bioworks on 11 of the 15 factors compared between the two stocks.

How does Lunai Bioworks compare to BioXcel Therapeutics?

Lunai Bioworks (NASDAQ:LNAI) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lunai Bioworks and Lunai Bioworks both had 1 articles in the media. Lunai Bioworks' average media sentiment score of 1.87 equaled BioXcel Therapeutics'average media sentiment score.

Company	Overall Sentiment
Lunai Bioworks	Very Positive
BioXcel Therapeutics	Very Positive

Lunai Bioworks has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

BioXcel Therapeutics has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
BioXcel Therapeutics	$640K	38.16	-$69.90M	-$3.79	N/A

Lunai Bioworks has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

BioXcel Therapeutics has a consensus price target of $11.00, indicating a potential upside of 1,310.26%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

BioXcel Therapeutics beats Lunai Bioworks on 9 of the 13 factors compared between the two stocks.

How does Lunai Bioworks compare to Gossamer Bio?

Lunai Bioworks (NASDAQ:LNAI) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Gossamer Bio had 5 more articles in the media than Lunai Bioworks. MarketBeat recorded 6 mentions for Gossamer Bio and 1 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.87 beat Gossamer Bio's score of 0.66 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Very Positive
Gossamer Bio	Positive

Gossamer Bio has a consensus target price of $3.20, indicating a potential upside of 1,740.14%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Gossamer Bio has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Gossamer Bio	$48.47M	0.84	-$170.37M	-$0.70	N/A

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 3.7% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lunai Bioworks has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Gossamer Bio	-235.00%	N/A	-112.04%

Lunai Bioworks has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Summary

Gossamer Bio beats Lunai Bioworks on 12 of the 15 factors compared between the two stocks.

How does Lunai Bioworks compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

In the previous week, Quince Therapeutics had 4 more articles in the media than Lunai Bioworks. MarketBeat recorded 5 mentions for Quince Therapeutics and 1 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.87 beat Quince Therapeutics' score of 0.45 indicating that Lunai Bioworks is being referred to more favorably in the news media.

Company	Overall Sentiment
Quince Therapeutics	Neutral
Lunai Bioworks	Very Positive

Quince Therapeutics' return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Quince Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Quince Therapeutics currently has a consensus price target of $260.00, indicating a potential upside of 730.41%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Quince Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.33
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Quince Therapeutics beats Lunai Bioworks on 11 of the 14 factors compared between the two stocks.

How does Lunai Bioworks compare to BeyondSpring?

Lunai Bioworks (NASDAQ:LNAI) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

In the previous week, Lunai Bioworks and Lunai Bioworks both had 1 articles in the media. BeyondSpring's average media sentiment score of 1.89 beat Lunai Bioworks' score of 1.87 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Very Positive
BeyondSpring	Very Positive

Lunai Bioworks has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

BeyondSpring has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
BeyondSpring	$1.75M	16.21	-$1.01M	-$0.12	N/A

BeyondSpring's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
BeyondSpring	N/A	N/A	-28.88%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BeyondSpring beats Lunai Bioworks on 9 of the 10 factors compared between the two stocks.

Get Lunai Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNAI vs. The Competition

Export

Metric	Lunai Bioworks	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.87M	$4.03B	$7.30B	$12.77B
Dividend Yield	N/A	3.63%	2.53%	10.79%
P/E Ratio	-6.00	11.42	272.49	24.13
Price / Sales	N/A	1,366.67	626.71	98.17
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	-0.24	16.88	13.14	6.23
Net Income	-$178.01M	-$22.76M	$3.47B	$348.07M
7 Day Performance	8.11%	1.55%	1.38%	0.66%
1 Month Performance	3.00%	11.71%	8.62%	4.84%
1 Year Performance	N/A	56.88%	25.90%	16.83%

Lunai Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNAI Lunai Bioworks	0.6621 of 5 stars	$2.40 +9.1%	N/A	N/A	$10.87M	N/A	N/A	20
MDXH MDxHealth	2.5911 of 5 stars	$0.81 +74.9%	$2.83 +250.7%	-77.7%	$39.99M	$107.88M	N/A	300	Gap Up High Trading Volume
BTAI BioXcel Therapeutics	2.6554 of 5 stars	$1.19 +5.3%	$11.00 +824.4%	-85.6%	$36.74M	$640K	N/A	90	Positive News Gap Up High Trading Volume
GOSS Gossamer Bio	2.6789 of 5 stars	$0.15 -9.5%	$3.20 +1,975.2%	-91.3%	$36.19M	$48.47M	N/A	180	Gap Down
QNCX Quince Therapeutics	2.6964 of 5 stars	$34.04 +5.0%	$310.50 +812.2%	-90.2%	$34.62M	N/A	N/A	60	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNAI) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lunai Bioworks (LNAI) Competitors

LNAI vs. MDXH, BTAI, GOSS, QNCX, and BYSI

How does Lunai Bioworks compare to MDxHealth?

Summary

How does Lunai Bioworks compare to BioXcel Therapeutics?

Summary

How does Lunai Bioworks compare to Gossamer Bio?

Summary

How does Lunai Bioworks compare to Quince Therapeutics?

Summary

How does Lunai Bioworks compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lunai Bioworks (LNAI) Competitors

LNAI vs. MDXH, BTAI, GOSS, QNCX, and BYSI

How does Lunai Bioworks compare to MDxHealth?

Does the media favor LNAI or MDXH?

Which has more volatility and risk, LNAI or MDXH?

Do analysts recommend LNAI or MDXH?

Is LNAI or MDXH more profitable?

Which has higher valuation and earnings, LNAI or MDXH?

Do institutionals & insiders have more ownership in LNAI or MDXH?

Summary

How does Lunai Bioworks compare to BioXcel Therapeutics?

Do insiders and institutionals believe in LNAI or BTAI?

Does the media favor LNAI or BTAI?

Which has more volatility & risk, LNAI or BTAI?

Which has stronger valuation and earnings, LNAI or BTAI?

Is LNAI or BTAI more profitable?

Do analysts prefer LNAI or BTAI?

Summary

How does Lunai Bioworks compare to Gossamer Bio?

Does the media refer more to LNAI or GOSS?

Do analysts rate LNAI or GOSS?

Which has higher earnings and valuation, LNAI or GOSS?

Do institutionals & insiders believe in LNAI or GOSS?

Is LNAI or GOSS more profitable?

Which has more risk & volatility, LNAI or GOSS?

Summary

How does Lunai Bioworks compare to Quince Therapeutics?

Which has higher valuation & earnings, QNCX or LNAI?

Does the media prefer QNCX or LNAI?

Is QNCX or LNAI more profitable?

Which has more risk and volatility, QNCX or LNAI?

Do analysts prefer QNCX or LNAI?

Do institutionals & insiders hold more shares of QNCX or LNAI?

Summary

How does Lunai Bioworks compare to BeyondSpring?

Does the media prefer LNAI or BYSI?

Which has more volatility and risk, LNAI or BYSI?

Which has preferable valuation and earnings, LNAI or BYSI?

Is LNAI or BYSI more profitable?

Do analysts prefer LNAI or BYSI?

Do insiders & institutionals hold more shares of LNAI or BYSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools